| First Author | Lerner EC | Year | 2023 |
| Journal | Nat Cancer | Volume | 4 |
| Issue | 9 | Pages | 1258-1272 |
| PubMed ID | 37537301 | Mgi Jnum | J:341187 |
| Mgi Id | MGI:7531917 | Doi | 10.1038/s43018-023-00600-4 |
| Citation | Lerner EC, et al. (2023) CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer 4(9):1258-1272 |
| abstractText | The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8(+) T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex (MHC) class I (MHC-I) molecules. Likewise, a classically described mechanism of tumor immune escape is tumor MHC-I downregulation. Here, we report that CD8(+) T cells maintain the capacity to kill tumor cells that are entirely devoid of MHC-I expression. This capacity proves to be dependent instead on interactions between T cell natural killer group 2D (NKG2D) and tumor NKG2D ligands (NKG2DLs), the latter of which are highly expressed on MHC-loss variants. Necessarily, tumor cell killing in these instances is antigen independent, although prior T cell antigen-specific activation is required and can be furnished by myeloid cells or even neighboring MHC-replete tumor cells. In this manner, adaptive priming can beget innate killing. These mechanisms are active in vivo in mice as well as in vitro in human tumor systems and are obviated by NKG2D knockout or blockade. These studies challenge the long-advanced notion that downregulation of MHC-I is a viable means of tumor immune escape and instead identify the NKG2D-NKG2DL axis as a therapeutic target for enhancing T cell-dependent anti-tumor immunity against MHC-loss variants. |
